HYPERTENSION, PORTAL
Clinical trials for HYPERTENSION, PORTAL explained in plain language.
Never miss a new study
Get alerted when new HYPERTENSION, PORTAL trials appear
Sign up with your email to follow new studies for HYPERTENSION, PORTAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Liver pressure drug trial halted early – what we know
Disease control TerminatedThis study tested a new medicine called Avenciguat (BI 685509) to lower high blood pressure in the liver's main vein, a condition called portal hypertension, in people with compensated cirrhosis. About 90 adults with cirrhosis from hepatitis B, C, or NASH took the drug alone or w…
Matched conditions: HYPERTENSION, PORTAL
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Liver pressure drug trial halted early
Disease control TerminatedThis study looked at whether a medicine called Avenciguat could lower high blood pressure in the main vein to the liver in adults with cirrhosis. Participants took either a low or high dose of the drug or a placebo twice a day for 24 weeks. The trial was terminated early, so resu…
Matched conditions: HYPERTENSION, PORTAL
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 18, 2026 12:01 UTC